Cargando…

Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy

Background: Market access stakeholders consider the adoption of Managed Entry Agreements (MEAs), however a clearly described methodology to quantify their implementation burden is not available in the public domain. Objective: To quantify the cost of implementing a performance-based MEA at the hospi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kefalas, Panos, Ali, Omar, Jørgensen, Jesper, Merryfield, Nick, Richardson, Tim, Meads, Adam, Mungapen, Laura, Durdy, Matthew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Routledge 2018
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104603/ https://www.ncbi.nlm.nih.gov/pubmed/30151078 http://dx.doi.org/10.1080/20016689.2018.1511679

Ejemplares similares

Data collection infrastructure for patient outcomes in the UK – opportunities and challenges for cell and gene therapies launching
por: Jørgensen, Jesper, et al.
Publicado: (2019)

Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries
por: Jørgensen, Jesper, et al.
Publicado: (2020)

Upgrading the SACT dataset and EBMT registry to enable outcomes-based reimbursement in oncology in England: a gap analysis and top-level cost estimate
por: Jørgensen, Jesper, et al.
Publicado: (2019)

The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson’s disease
por: Jørgensen, Jesper, et al.
Publicado: (2018)

Reimbursement of licensed cell and gene therapies across the major European healthcare markets
por: Jørgensen, Jesper, et al.
Publicado: (2015)

A price comparison of recently launched proprietary pharmaceuticals in the UK and the US
por: Jørgensen, Jesper, et al.
Publicado: (2016)

Annuity payments can increase patient access to innovative cell and gene therapies under England’s net budget impact test
por: Jørgensen, Jesper, et al.
Publicado: (2017)

Impact of Managed Entry Agreements on availability of and timely access to medicines: an ex-post evaluation of agreements implemented for oncology therapies in four countries
por: Efthymiadou, Olina, et al.
Publicado: (2022)

The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications
por: Ferrario, Alessandra, et al.
Publicado: (2017)

Market access pathways for cell therapies in France
por: Rémuzat, Cécile, et al.
Publicado: (2015)

Managed entry agreements
por: Muscolo, Luisa AA, et al.
Publicado: (2014)

Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel
por: Facey, Karen M., et al.
Publicado: (2021)

Managed Entry Agreements for Pharmaceuticals in the Context of Adaptive Pathways in Europe
por: Bouvy, Jacoline C., et al.
Publicado: (2018)

Introduction of managed entry agreements in Korea: Problem, policy, and politics
por: Kim, Hyungmin, et al.
Publicado: (2023)

The Hypothetical Rabbit
por: Kattan, Michael W.
Publicado: (2016)

Review on Hypothetical Implementing TGF-β Family Members in Glaucoma Therapy
por: Sosa, Ivan, et al.
Publicado: (2012)

Concise Review: The High Cost of High Tech Medicine: Planning Ahead for Market Access
por: Driscoll, Dawn, et al.
Publicado: (2017)

Healthcare Systems across Europe and the US: The Managed Entry Agreements Experience
por: Ciulla, Michele, et al.
Publicado: (2023)

A Proposal for Value-Based Managed Entry Agreements in an Environment of Technological Change and Economic Challenge for Publicly Funded Healthcare Systems
por: Xoxi, Entela, et al.
Publicado: (2022)

A hypothetical implementation of ‘Termination of Resuscitation’ protocol for out-of-hospital cardiac arrest
por: Nazeha, Nuraini, et al.
Publicado: (2021)

How Do Iranian Stakeholders Think About Pharmaceutical Managed Entry Agreements?
por: Shobeiri, Nikta, et al.
Publicado: (2022)

Stakeholder views of managed entry agreements: A literature review of national studies
por: Thanimalai, Subramaniam, et al.
Publicado: (2021)

Hypothetical thinking : dual processes in reasoning and judgement
por: Evans, Jonathan St. B. T., 1948-
Publicado: (2007)

Agreement between Family Members and the Physician’s View in the ICU Environment: Personal Experience as a Factor Influencing Attitudes towards Corresponding Hypothetical Situations
por: Stamou, Paraskevi, et al.
Publicado: (2023)

Competition continues for hypothetical particle
Publicado: (2009)

Health economic value of an innovation: delimiting the scope and framework of future market entry agreements
por: Launois, Robert, et al.
Publicado: (2014)

Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future
por: Pauwels, Kim, et al.
Publicado: (2017)

The Evolution of AIFA Registries to Support Managed Entry Agreements for Orphan Medicinal Products in Italy
por: Xoxi, Entela, et al.
Publicado: (2021)

How Managed Entry Agreements Influence the Patients’ Affordability to Biological Medicines—Bulgarian Example
por: Mitkova, Zornitsa, et al.
Publicado: (2023)

Cost-effective implementation of the Paris Agreement using flexible greenhouse gas metrics
por: Tanaka, Katsumasa, et al.
Publicado: (2021)

Reliability and agreement of a novel portable laser height metre
por: Sørensen, Gustav Valentin Blichfeldt, et al.
Publicado: (2020)

Structural Analysis of Hypothetical Proteins from Helicobacter pylori: An Approach to Estimate Functions of Unknown or Hypothetical Proteins
por: Park, Sung Jean, et al.
Publicado: (2012)

Cost effectiveness of abdominal aortic aneurysm screening and rescreening in men in a modern context: evaluation of a hypothetical cohort using a decision analytical model
por: Søgaard, Rikke, et al.
Publicado: (2012)

Intergovernmental molecular biology agreement for the establishment of the European Molecular Biology Conference
por: CERN Press Office. Geneva
Publicado: (1969)

Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis
por: A Vreman, Rick, et al.
Publicado: (2020)

Price and reimbursement for orphan medicines and managed entry agreements: does Italy need a framework?
por: Jommi, Claudio, et al.
Publicado: (2021)

Hypothetical membrane mechanisms in essential tremor
por: Shaikh, Aasef G, et al.
Publicado: (2008)

The Hypothetical A-Factor and Trypanosome Infection
por: Smith, George H., et al.
Publicado: (1937)

Aftermath of a hypothetical smallpox disaster.
por: Bardi, J
Publicado: (1999)

Memorandum: a hypothetical staging of ELECTRA
por: CERN. Geneva. LEP Experiments Committee
Publicado: (1982)

Cannot write session to /tmp/vufind_sessions/sess_v93uvpfkd095rj1gt83ss0nptk